"Weekly Dose of Optimism #197" — @packym
Friday, June 12, 2026. Five main items spanning cathedral completion, cellular reprogramming, cancer-targeting CRISPR, autonomous naval rescue, and AI-native industrial robotics. Paid sponsor: Pangram (AI detection for compliance). Extra doses (paywalled) include science breakthroughs, Poseidon, Prometheus, Zeno Power, and Flock Safety.
Why this is in the vault
Saronic's first real-world rescue mission is a direct capital-cycle signal: autonomous defense hardware is now operational, not just announced. Standard Bots' $1B valuation at domestic manufacturing scale is the robotics-industrial inflection RDCO's Markov thesis needs to track. The cellular reprogramming trial (Life Biosciences/Sinclair lineage) and Doudna's CRISPR work represent the longevity and biotech frontier that shows up periodically in WDoO and has weak but non-zero relevance to healthcare-adjacent data plays.
⚠️ Sponsorship
Pangram — AI detection platform for compliance teams. Unrelated to editorial content; straightforward ad block. No Not Boring Capital apparent relationship.
Issue contents
La Sagrada Família — Tower of Jesus Christ blessed by Pope Leo XIV — 3D modeling, CNC machining, Lidar, and VR enabled completion of Gaudí's design a century after his death. Makes Sagrada Família the world's tallest Catholic church. (Third-party coverage, Not Boring original framing.)
Life Biosciences cellular reprogramming trial — First human trial of partial reprogramming using modified Yamanaka factors, targeting glaucoma via optic nerve cell rejuvenation. Builds on David Sinclair's Harvard mouse-vision work. Source: Nature (Heidi Ledford). (Third-party; no Not Boring Capital relationship verified in public round disclosures.)
Doudna/IGI CRISPR-Cas12a2 for p53-mutant cancer cells — Selectively destroys cancer cells carrying p53 mutations (present in up to 90% of aggressive cancers) while leaving healthy cells intact. Source: Innovative Genomics Institute. (Third-party; could not verify Not Boring Capital relationship — treat as messenger.)
Saronic Corsair autonomous surface vessel rescues Apache crew — First U.S. military rescue using an autonomous drone boat, in the Strait of Hormuz, one week after Saronic launched the larger Marauder vessel. Source: New York Times. (Third-party; Saronic is a well-known Not Boring Capital portfolio company — relationship known/disclosed in prior coverage.)
Standard Bots raises $200M at $1B valuation — America's largest AI-native industrial robot manufacturer; goal is 10% of U.S. industrial robots deployed by 2027. Co-founder Evan Beard previously co-authored with Packy in January 2026. (Cross-promo adjacent — prior co-authorship, no explicit equity disclosure in this issue; treat as potentially non-arm's-length.)
Mapping against Ray Data Co
Saronic (medium-strong): Operational autonomous defense hardware is a Phase 2→3 transition signal for the defense-tech capital cycle. The Markov phase-tracker's job is reading exactly these signals — Saronic's first live rescue is the kind of "proof of deployment" event that historically precedes procurement scale-up. Worth a note against the [[2026-05-27-markov-equities-pipeline-spec]].
Standard Bots (medium): Domestic AI-native robot manufacturing at $1B fits the industrial automation thread of the capital cycle thesis. The 2027 10%-of-U.S.-robots target is a concrete benchmark to track. The Evan Beard co-authorship flag means this item should be treated as potentially color-boosted — verify via third-party sources before incorporating into any thesis artifact.
Biotech items (weak): Life Biosciences and Doudna CRISPR are scientifically significant but map weakly to current RDCO work streams. File as ambient signal on longevity/biotech frontier; no action warranted.
La Sagrada Família (weak): Technology-enables-completion frame is a nice optimism hook but has no operational RDCO mapping.
Curation section — notes
| Item | Source type | Sponsor/portfolio flag |
|---|---|---|
| La Sagrada Família | Third-party (Not Boring original framing) | None detected |
| Life Biosciences trial | Third-party (Nature) | Could not verify Not Boring Capital relationship |
| Doudna CRISPR | Third-party (IGI) | Could not verify Not Boring Capital relationship |
| Saronic Corsair rescue | Third-party (NYT) | Known Not Boring Capital portfolio company — relationship previously disclosed in Not Boring coverage |
| Standard Bots | Third-party (X announcement) | Prior co-authorship with Packy (Jan 2026); no explicit equity disclosure in this issue |
Pangram sponsor block is clearly delineated and unrelated to editorial items.
Related
- [[2026-06-10-not-boring-return-on-tokens]]
- [[2026-06-05-not-boring-wdoo-196]]
- [[2026-05-27-markov-equities-pipeline-spec]]
- [[2026-06-11-ark-invest-ai-infrastructure-buildout]]